ReviewCancer gene therapy2025
Old versus new: upstream and downstream of promyelocytic leukemia zinc finger protein.
Review in Cancer gene therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Promyelocytic leukemia zinc finger (PLZF) is a member of the zinc finger protein family and has been extensively studied due to its crucial role in influencing stem cell self-renewal, spermatogenesis, T cell differentiation, tumorigenesis, and development. Its function is regulated by multidimensional and multilevel regulation. Recent studies have explored the mechanism of action of PLZF in different diseases and related treatment strategies. This study aimed to summarize the regulatory mechanisms underlying PLZF expression and function, and update the latest PLZF regulatory targets and interacting molecules. We also summarized the mechanism by which PLZF promoted the transcriptional activation of target genes, besides its role as a transcriptional repressor. This study revealed a more detailed upstream and downstream regulatory mechanism of PLZF, providing directions for future research.
Indexed as
Identifiers
40348913What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.